{"disease":{"id":"neurofibromatosis-type-1","name":"neurofibromatosis type 1"},"drugs":{"marketed":[{"drug_id":"selumetinib","indication_name":"Neurofibromatosis Type 1 with Symptomatic, Inoperable Plexiform Neurofibromas","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Koselugo","generic_name":"selumetinib","company_name":"ASTRAZENECA LP","drug_phase":"marketed","molecular_target":"AP2-associated protein kinase 1","drug_class":"Kinase Inhibitor [EPC]","quality_score":75,"revenue":null,"mechanism":"Selumetinib is an inhibitor of mitogen-activated protein kinase kinases 1 and 2 (MEK1/2)."},{"drug_id":"selumetinib","indication_name":"Treatment of adult and pediatric patients 1 year of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Koselugo","generic_name":"selumetinib","company_name":"ASTRAZENECA LP","drug_phase":"marketed","molecular_target":"AP2-associated protein kinase 1","drug_class":"Kinase Inhibitor [EPC]","quality_score":75,"revenue":null,"mechanism":"Selumetinib is an inhibitor of mitogen-activated protein kinase kinases 1 and 2 (MEK1/2)."},{"drug_id":"selumetinib","indication_name":"Treatment of adult and pediatric patients 1 year of age and older with neurofibromatosis type 1 (NF1)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Koselugo","generic_name":"selumetinib","company_name":"ASTRAZENECA LP","drug_phase":"marketed","molecular_target":"AP2-associated protein kinase 1","drug_class":"Kinase Inhibitor [EPC]","quality_score":75,"revenue":null,"mechanism":"Selumetinib is an inhibitor of mitogen-activated protein kinase kinases 1 and 2 (MEK1/2)."}],"pipeline":[],"offLabel":[],"totalMarketed":3,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT00026780","title":"Eligibility Screening for a NCI Pediatric Oncology Branch Research Study","phase":"","overall_status":"COMPLETED","enrollment_count":1720,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03050268","title":"Familial Investigations of Childhood Cancer Predisposition","phase":"","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"St. Jude Children's Research Hospital","has_results":false},{"nct_id":"NCT07327164","title":"Precision Medicine for Neurocutaneous Syndromes in Western China","phase":"","overall_status":"COMPLETED","enrollment_count":1200,"lead_sponsor_name":"West China Hospital","has_results":false},{"nct_id":"NCT05954416","title":"FARD (RaDiCo Cohort) (RaDiCo-FARD)","phase":"","overall_status":"RECRUITING","enrollment_count":900,"lead_sponsor_name":"Institut National de la Santé Et de la Recherche Médicale, France","has_results":false},{"nct_id":"NCT03757247","title":"Prevalence of Constitutional Mismatch-repair Deficiency Among Suspected Neurofibromatosis Type 1/Legius Syndrome Children Without a Malignancy and Without a NF1 or SPRED1 Mutation","phase":"","overall_status":"UNKNOWN","enrollment_count":670,"lead_sponsor_name":"Medical University Innsbruck","has_results":false},{"nct_id":"NCT00684398","title":"Adaptation and Quality of Life Among Adults With Neurofibromatosis Type I","phase":"","overall_status":"COMPLETED","enrollment_count":645,"lead_sponsor_name":"National Human Genome Research Institute (NHGRI)","has_results":false},{"nct_id":"NCT01445314","title":"Analysis of Data Collected From Individuals Administered Neurobehavioral Assessments","phase":"","overall_status":"COMPLETED","enrollment_count":598,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05581511","title":"Natural History Study of Cutaneous Neurofibromas in People With NF1","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":500,"lead_sponsor_name":"Johns Hopkins University","has_results":false},{"nct_id":"NCT00111384","title":"Study of Disease Severity in Adults With Neurofibromatosis Type 1 (NF1)","phase":"","overall_status":"COMPLETED","enrollment_count":313,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT00924196","title":"Natural History Study of Patients With Neurofibromatosis Type I","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":259,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01089101","title":"Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":217,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07221331","title":"Prevalence, Clinical Characteristics, Progression, and Management of Neurofibromatosis Type 1 in Egypt (NF1-Egy)","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT03871257","title":"A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":165,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03975829","title":"Pediatric Long-Term Follow-up and Rollover Study","phase":"PHASE4","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":163,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05388370","title":"PASS of Paediatric Patients Initiating Selumetinib","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":124,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT03962543","title":"MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":114,"lead_sponsor_name":"SpringWorks Therapeutics, Inc.","has_results":true},{"nct_id":"NCT06880991","title":"Development of Patient-Reported Outcome Measures Assessing Tumor Visibility and Appearance Concerns in Neurofibromatosis Type 1: A Qualitative Study","phase":"","overall_status":"RECRUITING","enrollment_count":110,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01362803","title":"AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":99,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01553149","title":"Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":75,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06507748","title":"A Study to Evaluate the Feasibility of a Physiologic Biomarker to Assess Pain and Other Sensory Problems Using Pupillometry in Participants With Neurofibromatosis Type 1 (NF1)","phase":"NA","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02471339","title":"Acceptance and Commitment Training for Adolescents and Young Adults With Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":66,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04212351","title":"Frameshift Peptides of Children With NF1","phase":"","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Children's National Research Institute","has_results":false},{"nct_id":"NCT05149469","title":"Molecular Aspects of Preimplantation Genetic Diagnosis for NF1","phase":"","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"University Hospital, Strasbourg, France","has_results":false},{"nct_id":"NCT04201457","title":"A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":57,"lead_sponsor_name":"Pediatric Brain Tumor Consortium","has_results":false},{"nct_id":"NCT01125046","title":"Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"Northwestern University","has_results":true},{"nct_id":"NCT03231306","title":"Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":45,"lead_sponsor_name":"University of Alabama at Birmingham","has_results":true},{"nct_id":"NCT05683678","title":"US Selumetinib Registry","phase":"","overall_status":"TERMINATED","enrollment_count":37,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT05309668","title":"Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PN","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":36,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT03888248","title":"Whole-body Vibration in Children With Neurofibromatosis Type 1","phase":"NA","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Manchester University NHS Foundation Trust","has_results":false},{"nct_id":"NCT04153344","title":"Function of the Pigment Epithelium in Patients With Type 1 Neurofibromatosis","phase":"","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT02584413","title":"Hypotonia and Neurofibromatosis Type 1 (NF1) Glioma","phase":"NA","overall_status":"TERMINATED","enrollment_count":29,"lead_sponsor_name":"Washington University School of Medicine","has_results":false},{"nct_id":"NCT02415153","title":"Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":29,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01968590","title":"Vitamin D Supplementation for Adults With Neurofibromatosis Type 1 (NF1)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":26,"lead_sponsor_name":"University of Utah","has_results":false},{"nct_id":"NCT03649165","title":"A Study to Evaluate Bioavailability and Food Effect of Selumetinib (AZD6244) in Healthy Male Participants","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT05101148","title":"Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":24,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT00314119","title":"Natural History and Biology of Skin Neurofibromas in Neurofibromatosis Type 1","phase":"","overall_status":"COMPLETED","enrollment_count":17,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03326388","title":"Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":14,"lead_sponsor_name":"Great Ormond Street Hospital for Children NHS Foundation Trust","has_results":false},{"nct_id":"NCT04495127","title":"Selumetinib Paediatric NF1 Japan Study","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT02839720","title":"Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":11,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03190915","title":"Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":10,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02700230","title":"Vaccine Therapy in Treating Patients with Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by Surgery","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":9,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03332030","title":"Stem Cells in NF1 Patients With Tumors of the Central Nervous System","phase":"","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Roger Packer","has_results":false},{"nct_id":"NCT05825365","title":"Selumetinib in Chinese Paediatric With Post-operative NF1-PNs, PhaseⅡ, Double-Blinded, Placebo-Controlled Study","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT05028166","title":"Individual Patient Compassionate Use of Mirdametinib","phase":"","overall_status":"AVAILABLE","enrollment_count":null,"lead_sponsor_name":"SpringWorks Therapeutics, Inc.","has_results":false}],"total":44},"guidelines":[],"source":"Drug Landscape verified database"}